Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3704395 | 0.90 | MRGPRX4 (0.43) | ENPP2MRGPRX4PTGER1 | |
| SCHEMBL4568482 | 0.88 | PARP1 (0.46) | MRGPRX4 | |
| SCHEMBL4568594 | 0.88 | MRGPRX4 (0.44) | ENPP2MRGPRX4PTGER1 | |
| SCHEMBL4568169 | 0.88 | ENPP2 (0.41) | ENPP2MRGPRX4PTGER1 | |
| SCHEMBL15998667 | 0.85 | HCAR2 (0.36) | ENPP2PTGER1 | |
| SCHEMBL4568163 | 0.84 | ENPP2 (0.50) | ENPP2MRGPRX4PTGER1 | |
| SCHEMBL4568167 | 0.84 | PTGS2 (0.40) | ENPP2PTGER1 | |
| SCHEMBL3706414 | 0.83 | PPARG (0.43) | ENPP2 | |
| SCHEMBL4568213 | 0.83 | GPR17 (0.46) | ENPP2MRGPRX4PTGER1 | |
| SCHEMBL3712703 | 0.82 | PTGER1 (0.38) | MRGPRX4PTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2474530-B1 | INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL (JP) | 2014-09-03 | — | — | EP | disclosed |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | PTGER1, CYSLTR1, LTB4R | ENPP2 595/4885MRGPRX4 273/4885PTGER1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.